Antiplatelet and Anticoagulation    The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ Catheter Cardiovasc Interv (2009) 73; 222-3 F. Zijlstra Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial Am Heart J (2009) 157; 60 e1-9 . Yong, J. Rankin, L. Ferguson, J. Thom, J. French, D. Brieger, D. P. Chew, R. Dick, D. Eccleston, B. Hockings, D. Walters, A. Whelan and J. W. Eikelboom Anticoagulation with the direct thrombin inhibitor argatroban in patients presenting with acute coronary syndromes Catheter Cardiovasc Interv (2009) . W. Yeh, S. J. Baron, J. L. Healy, E. Pomerantsev, I. A. McNulty, I. Cruz-Gonzalez and I. K. Jang Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad Eur Heart J (2008) 29; 1729-38 Y. Yano, T. Ohmori, S. Hoshide, S. Madoiwa, K. Yamamoto, T. Katsuki, T. Mitsuhashi, J. Mimuro, K. Shimada, K. Kario and Y. Sakata Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial Lancet (2008) 371; 1353-63 S. D. Wiviott, E. Braunwald, C. H. McCabe, I. Horvath, M. Keltai, J. P. Herrman, F. Van de Werf, W. E. Downey, B. M. Scirica, S. A. Murphy and E. M. Antman Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation (2008) 118; 1626-36 S. D. Wiviott, E. Braunwald, D. J. Angiolillo, S. Meisel, A. J. Dalby, F. W. Verheugt, S. G. Goodman, R. Corbalan, D. A. Purdy, S. A. Murphy, C. H. McCabe and E. M. Antman Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial J Am Coll Cardiol (2008) 52; 807-14 H. D. White, E. M. Ohman, A. M. Lincoff, M. E. Bertrand, A. Colombo, B. T. McLaurin, D. A. Cox, S. J. Pocock, J. A. Ware, S. V. Manoukian, A. J. Lansky, R. Mehran, J. W. Moses and G. W. Stone The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial Am Heart J (2009) 157; 125-31 H. D. White, R. Gallo, M. Cohen, P. G. Steg, P. E. Aylward, C. Bode, S. Steinhubl and G. Montalescot Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial J Am Coll Cardiol (2008) 51; 1734-41 H. D. White, D. P. Chew, J. W. Hoekstra, C. D. Miller, C. V. Pollack, Jr., F. Feit, A. M. Lincoff, M. Bertrand, S. Pocock, J. Ware, E. M. Ohman, R. Mehran and G. W. Stone Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry Am Heart J (2008) 155; 361-8 T. Y. Wang, L. A. Robinson, F. S. Ou, M. T. Roe, E. M. Ohman, W. B. Gibler, S. C. Smith, Jr., E. D. Peterson and R. C. Becker Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative Eur Heart J (2008) 29; 1103-9 T. Y. Wang, A. Y. Chen, E. D. Peterson, R. C. Becker, W. B. Gibler, E. M. Ohman and M. T. Roe Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J (2008) 29; 21-30 L. Wallentin, C. Varenhorst, S. James, D. Erlinge, O. O. Braun, J. A. Jakubowski, A. Sugidachi, K. J. Winters and A. Siegbahn Prasugrel versus clopidogrel N Engl J Med (2008) 358; 1299; author reply 99-301 F. von Lewinski, J. Riggert and W. Paulus Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study Lancet (2008) 371; 1915-20 P. J. Vlaar, T. Svilaas, I. C. van der Horst, G. F. Diercks, M. L. Fokkema, B. J. de Smet, A. F. van den Heuvel, R. L. Anthonio, G. A. Jessurun, E. S. Tan, A. J. Suurmeijer and F. Zijlstra Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review Circulation (2008) 118; 1828-36 P. J. Vlaar, T. Svilaas, K. Damman, B. J. de Smet, J. G. Tijssen, H. L. Hillege and F. Zijlstra Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin Am Heart J (2009) 157; 562 e1-9 C. Varenhorst, S. James, D. Erlinge, O. O. Braun, J. T. Brandt, K. J. Winters, J. A. Jakubowski, S. Olofsson, L. Wallentin and A. Siegbahn Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial Lancet (2008) 372; 537-46 A. W. Van't Hof, J. Ten Berg, T. Heestermans, T. Dill, R. C. Funck, W. van Werkum, J. H. Dambrink, H. Suryapranata, G. van Houwelingen, J. P. Ottervanger, P. Stella, E. Giannitsis and C. Hamm Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction in reocclusion to improved long-term clinical outcome Am Heart J (2009) 157; 532-40 P. J. van den Bergh, P. C. Kievit, M. A. Brouwer, W. R. Aengevaeren, G. Veen and F. W. Verheugt Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol (2008) 51; 1925-34 D. Trenk, W. Hochholzer, M. F. Fromm, L. E. Chialda, A. Pahl, C. M. Valina, C. Stratz, P. Schmiebusch, H. P. Bestehorn, H. J. Buttner and F. J. Neumann Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial Circulation (2008) 118; 49-57 H. Thiele, K. Schindler, J. Friedenberger, I. Eitel, G. Furnau, E. Grebe, S. Erbs, A. Linke, S. Mobius-Winkler, D. Kivelitz and G. Schuler Temporal course of pregnancy-associated plasma protein-A in angioplasty-treated ST-elevation myocardial infarction patients and potential significance of concomitant heparin administration Am J Cardiol (2009) 103; 29-35 C. J. Terkelsen, C. Oxvig, B. L. Norgaard, S. Glerup, T. S. Poulsen, J. F. Lassen, H. J. Moller, L. Thuesen, E. Falk, T. T. Nielsen and H. R. Andersen Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial) Am J Cardiol (2009) 103; 785-90 N. Taglieri, F. Saia, V. Guiducci, S. Tondi, F. Conrotto, C. Marrozzini, G. Rocchi, E. Biagini, M. L. Reggiani, P. Giacometti, G. Piovaccari, A. Manari and A. Marzocchi Clopidogrel in acute coronary syndrome: to genotype or not? Lancet (2009) 373; 276-8 R. F. Storey Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med (2008) 358; 2218-30 G. W. Stone, B. Witzenbichler, G. Guagliumi, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, F. Hartmann, B. J. Gersh, S. J. Pocock, G. Dangas, S. C. Wong, A. J. Kirtane, H. Parise and R. Mehran Aspirin following PCI: too much of a good thing Eur Heart J (2009) S. R. Steinhubl and P. B. Berger The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention J Am Coll Cardiol (2008) 52; 1293-8 E. Stabile, W. Nammas, L. Salemme, G. Sorropago, A. Cioppa, T. Tesorio, V. Ambrosini, E. Campopiano, G. Popusoi, G. Biondi Zoccai and P. Rubino Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med (2009) 360; 363-75 T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, N. Meneveau, P. G. Steg, J. Ferrieres, N. Danchin and L. Becquemont Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel Am Heart J (2009) 157; 148 e1-5 . M. Siller-Matula, A. O. Spiel, I. M. Lang, G. Kreiner, G. Christ and B. Jilma Calcium-channel blockers reduce the antiplatelet effect of clopidogrel J Am Coll Cardiol (2008) 52; 1557-63 J. M. Siller-Matula, I. Lang, G. Christ and B. Jilma Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention Eur Heart J (2008) 29; 1504-9 D. Sibbing, G. Busch, S. Braun, S. Jawansky, A. Schomig, A. Kastrati, I. Ott and N. von Beckerath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol (2009) 53; 849-56 D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, A. Schomig, A. Kastrati and N. von Beckerath Multiple mechanisms affect the clopidogrel response J Am Coll Cardiol (2009) 53; 900-1; author reply 01 G. Siasos, D. Tousoulis and C. Stefanadis Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease Am J Cardiol (2008) 101; 1741-6 M. H. Shishehbor, L. P. Oliveira, M. S. Lauer, D. L. Sprecher, K. Wolski, L. Cho, B. J. Hoogwerf and S. L. Hazen Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial Am Heart J (2008) 155; 93 e1-7 V. L. Serebruany, A. I. Malinin, A. Pokov, G. Barsness and D. F. Hanley The challenge of monitoring platelet response after clopidogrel Eur Heart J (2008) 29; 2833-4 V. L. Serebruany and S. Goto Prasugrel versus clopidogrel N Engl J Med (2008) 358; 1298; author reply 99-301 V. Serebruany The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study J Am Coll Cardiol (2008) 52; 1826-33 J. Saw, E. H. Madsen, S. Chan and E. Maurer-Spurej Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use Am Heart J (2008) 155; 910-7 M. S. Sabatine, H. N. Hamdalla, S. R. Mehta, K. A. Fox, E. J. Topol, S. R. Steinhubl and C. P. Cannon Which patients receiving warfarin can be treated safely with a drug-eluting stent? Heart (2008) 94; 275-7 A. D. Ryding and A. P. Banning Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy Am J Cardiol (2008) 102; 1618-23 R. Rossini, G. Musumeci, C. Lettieri, M. Molfese, L. Mihalcsik, P. Mantovani, V. Sirbu, T. A. Bass, F. Della Rovere, A. Gavazzi and D. J. Angiolillo Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era? Eur Heart J (2008) 29; 429-31 M. Roffi and D. Mukherjee Cytochrome P450 2C19 polymorphism and clopidogrel after MI Lancet (2009) 373; 1172; author reply 72-3 R. Ramaraj Clinical follow-up in endovascular treatment for TASC C-D lesions in femoro-popliteal segment Catheter Cardiovasc Interv (2009) 73; 701-5 M. Rabellino, T. Zander, S. Baldi, L. Garcia Nielsen, F. J. Aragon-Sanchez, I. Zerolo, R. Llorens and M. Maynar Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease Am J Cardiol (2008) 101; 1359-63 R. Qayyum, D. M. Becker, L. R. Yanek, T. F. Moy, L. C. Becker, N. Faraday and D. Vaidya Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers Am J Cardiol (2008) 102; 790-5 M. J. Price and P. S. Teirstein Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J (2008) 29; 992-1000 M. J. Price, S. Endemann, R. R. Gollapudi, R. Valencia, C. T. Stinis, J. P. Levisay, A. Ernst, N. S. Sawhney, R. A. Schatz and P. S. Teirstein Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes J Am Coll Cardiol (2008) 52; 1758-68 D. S. Pinto, G. W. Stone, C. Shi, E. S. Dunn, M. R. Reynolds, M. York, J. Walczak, R. H. Berezin, R. Mehran, B. T. McLaurin, D. A. Cox, E. M. Ohman, A. M. Lincoff and D. J. Cohen Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors J Am Coll Cardiol (2008) 52; 1038-9; author reply 39 E. Pezalla, D. Day and I. Pulliadath The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial Eur Heart J (2008) 29; 324-31 R. J. Peters, C. Joyner, J. P. Bassand, R. Afzal, S. Chrolavicius, S. R. Mehta, J. Oldgren, L. Wallentin, A. Budaj, K. A. Fox and S. Yusuf Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study J Am Coll Cardiol (2008) 52; 1128-33 G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio and G. Di Sciascio Prasugrel versus clopidogrel N Engl J Med (2008) 358; 1298-9; author reply 99-301 V. Pasceri, G. Patti and G. Di Sciascio Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network Eur Heart J (2009) 30; 33-43 P. Ortolani, A. Marzocchi, C. Marrozzini, T. Palmerini, F. Saia, N. Taglieri, F. Baldazzi, G. Dall'Ara, P. Nardini, S. Gianstefani, P. Guastaroba, R. Grilli and A. Branzi Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment Eur Heart J (2008) 29; 315-23 . Oldgren, L. Wallentin, R. Afzal, J. P. Bassand, A. Budaj, S. Chrolavicius, K. A. Fox, C. B. Granger, S. R. Mehta, P. Pais, R. J. Peters, D. Xavier, J. Zhu and S. Yusuf Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals Am Heart J (2008) 155; 493 e1-8 . Oldgren, N. Johnston and A. Siegbahn Clopidogrel treatment and the MEND-CABG II trial JAMA (2008) 300; 1021; author reply 21-2 J. Oh, N. Hong and S. M. Kang Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy Eur Heart J (2008) 29; 984-91 M. O'Donoghue, D. A. Morrow, C. P. Cannon, W. Guo, S. A. Murphy, C. M. Gibson and M. S. Sabatine Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan Arteriosclerosis Longitudinal Study Circulation (2008) 118; 2694-701 T. Ninomiya, Y. Kiyohara, Y. Tokuda, Y. Doi, H. Arima, A. Harada, Y. Ohashi and H. Ueshima One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial Eur Heart J (2008) 29; 455-61 G. Ndrepepa, A. Kastrati, J. Mehilli, F. J. Neumann, J. ten Berg, O. Bruskina, F. Dotzer, M. Seyfarth, J. Pache, J. Dirschinger, P. B. Berger and A. Schomig Optimal treatment of renal artery in-stent restenosis: repeat stent placement versus angioplasty alone Catheter Cardiovasc Interv (2008) 71; 701-5 Z. M. N'Dandu, R. A. Badawi, C. J. White, M. A. Grise, J. P. Reilly, J. S. Jenkins, T. J. Collins and S. R. Ramee A thrombus stuck in the ostium of the coronary artery Eur Heart J (2009) 30; 24 T. Nakahara, M. Manita and M. Kurabayashi Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction Eur Heart J (2008) 29; 445-54 M. Nahrendorf, E. Aikawa, J. L. Figueiredo, L. Stangenberg, S. W. van den Borne, W. M. Blankesteijn, D. E. Sosnovik, F. A. Jaffer, C. H. Tung and R. Weissleder Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial Eur Heart J (2008) 29; 2473-9 S. A. Murphy, E. M. Antman, S. D. Wiviott, G. Weerakkody, G. Morocutti, K. Huber, J. Lopez-Sendon, C. H. McCabe and E. Braunwald Antithrombotic therapy to support primary PCI N Engl J Med (2008) 358; 2280-2 D. A. Morrow Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet (2009) 373; 723-31 G. Montalescot, S. D. Wiviott, E. Braunwald, S. A. Murphy, C. M. Gibson, C. H. McCabe and E. M. Antman Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial Eur Heart J (2008) 29; 462-71 G. Montalescot, M. Cohen, G. Salette, W. J. Desmet, C. Macaya, P. E. Aylward, P. G. Steg, H. D. White, R. Gallo and S. R. Steinhubl Mechanical reperfusion: treat well, treat on time too Lancet (2008) 372; 509-10 G. Montalescot Cytochrome P450 2C19 polymorphism and clopidogrel after MI Lancet (2009) 373; 1171-2; author reply 72-3 J. Miao, R. Liu and Z. Li Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes Am Heart J (2008) 156; 209-15 C. Melloni, K. P. Alexander, A. Y. Chen, L. K. Newby, M. T. Roe, N. M. Allen LaPointe, C. V. Pollack, Jr., W. B. Gibler, E. M. Ohman and E. D. Peterson Transient ST-elevation myocardial infarction: clinical course with intense medical therapy and early invasive approach, and comparison with persistent ST-elevation myocardial infarction Am Heart J (2008) 155; 848-54 S. R. Meisel, Y. Dagan, D. S. Blondheim, S. Dacca, M. Shochat, M. Kazatsker, A. Asif, A. Frimerman and A. Shotan Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials Circulation (2008) 118; 2038-46 S. R. Mehta, W. E. Boden, J. W. Eikelboom, M. Flather, P. G. Steg, A. Avezum, R. Afzal, L. S. Piegas, D. P. Faxon, P. Widimsky, A. Budaj, S. Chrolavicius, H. J. Rupprecht, S. Jolly, C. B. Granger, K. A. Fox, J. P. Bassand and S. Yusuf The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale Am Heart J (2008) 156; 44-56 . Mehran, B. Brodie, D. A. Cox, C. L. Grines, B. Rutherford, D. L. Bhatt, G. Dangas, F. Feit, E. M. Ohman, H. Parise, M. Fahy, A. J. Lansky and G. W. Stone Abciximab in Patients With Acute ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading. A Randomized Double-Blind Trial Circulation (2009) J. Mehilli, A. Kastrati, S. Schulz, S. Frungel, S. G. Nekolla, W. Moshage, F. Dotzer, K. Huber, J. Pache, J. Dirschinger, M. Seyfarth, S. Martinoff, M. Schwaiger and A. Schomig Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med (2009) 360; 354-62 J. L. Mega, S. L. Close, S. D. Wiviott, L. Shen, R. D. Hockett, J. T. Brandt, J. R. Walker, E. M. Antman, W. Macias, E. Braunwald and M. S. Sabatine Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med (2009) 360; 354-62 J. L. Mega, S. L. Close, S. D. Wiviott, L. Shen, R. D. Hockett, J. T. Brandt, J. R. Walker, E. M. Antman, W. Macias, E. Braunwald and M. S. Sabatine Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction Am J Cardiol (2008) 102; 524-9 S. Matetzky, P. Fefer, B. Shenkman, D. Varon, N. Savion and H. Hod Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial Eur Heart J (2008) 29; 2972-80 A. Marzocchi, A. Manari, G. Piovaccari, C. Marrozzini, S. Marra, P. Magnavacchi, P. Sangiorgio, L. Marinucci, N. Taglieri, G. Gordini, N. Binetti, V. Guiducci, N. Franco, M. L. Reggiani and F. Saia Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention Catheter Cardiovasc Interv (2009) 73; 214-21 . D. Marmur, S. Poludasu, J. Lazar and E. Cavusoglu Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study Am Heart J (2009) 157; 658-65 K. H. Mak, D. L. Bhatt, M. Shao, G. J. Hankey, J. D. Easton, K. A. Fox and E. J. Topol Noncardiac Surgery and Antiplatelet Therapy Following Coronary Artery Stenting Heart (2009) M. J. Luckie, R. S. Khattar and D. G. Fraser Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic Eur Heart J (2008) 29; 138; author reply 38-9 M. Lotrionte, G. G. Biondi-Zoccai, P. Agostoni and I. Sheiban Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial Eur Heart J (2008) 29; 1827-33 . D. Lopes, K. P. Alexander, G. Marcucci, H. D. White, S. Spinler, J. Col, P. E. Aylward, R. M. Califf and K. W. Mahaffey Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial J Am Coll Cardiol (2009) 53; 1021-30 R. D. Lopes, K. P. Alexander, S. V. Manoukian, M. E. Bertrand, F. Feit, H. D. White, C. V. Pollack, Jr., J. Hoekstra, B. J. Gersh, G. W. Stone and E. M. Ohman Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study Circulation (2009) 119; 37-43 W. Lieb, M. G. Larson, E. J. Benjamin, X. Yin, G. H. Tofler, J. Selhub, P. F. Jacques, T. J. Wang, J. A. Vita, D. Levy, R. S. Vasan and G. F. Mitchell Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study Circulation (2009) 119; 37-43 W. Lieb, M. G. Larson, E. J. Benjamin, X. Yin, G. H. Tofler, J. Selhub, P. F. Jacques, T. J. Wang, J. A. Vita, D. Levy, R. S. Vasan and G. F. Mitchell Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial Circulation (2008) 117; 553-9 J. S. Li, E. Yow, K. Y. Berezny, P. M. Bokesch, M. Takahashi, T. P. Graham, Jr., S. P. Sanders, D. Sidi, D. Bonnet, P. Ewert, L. K. Jennings and A. D. Michelson Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction Am J Cardiol (2008) 101; 435-9 E. I. Lev, R. Kornowski, H. Vaknin-Assa, D. Brosh, S. Fuchs, A. Battler and A. Assali Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome Am Heart J (2008) 156; 177-84 S. Leung, D. Gallup, K. W. Mahaffey, M. Cohen, E. M. Antman, S. G. Goodman, R. A. Harrington, A. Langer, P. Aylward, J. J. Ferguson and R. M. Califf Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome Am Heart J (2009) 157; 375-82 G. Lemesle, C. Delhaye, A. Sudre, D. Broucqsault, G. Rosey, C. Bauters and J. M. Lablanche Impact of bivalirudin on in-hospital bleeding and six-month outcomes in octogenarians undergoing percutaneous coronary intervention Catheter Cardiovasc Interv (2009) G. Lemesle, A. De Labriolle, L. Bonello, A. Syed, S. Collins, G. Maluenda, R. Torguson, K. Kaneshige, Z. Xue, W. O. Suddath, L. F. Satler, K. M. Kent, J. Lindsay, A. D. Pichard and R. Waksman Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial Catheter Cardiovasc Interv (2008) 72; 917-24 A. J. Lansky, Y. Tsuchiya, M. Brener, R. Mehran, E. Cristea, C. Pietras, C. L. Grines, D. A. Cox, E. Garcia, J. E. Tcheng, G. Guagliumi, T. Stuckey, M. Turco, J. D. Carroll, B. D. Rutherford, M. B. Leon, J. Moses and G. W. Stone Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study J Am Coll Cardiol (2008) 51; 1066-72 P. L. L'Allier, G. Ducrocq, N. Pranno, S. Noble, R. Ibrahim, J. C. Gregoire, F. Azzari, A. Nozza, C. Berry, S. Doucet, B. Labarthe, P. Theroux and J. C. Tardif Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology Eur Heart J (2009) 30; 426-35 W. Kuliczkowski, A. Witkowski, L. Polonski, C. Watala, K. Filipiak, A. Budaj, J. Golanski, D. Sitkiewicz, J. Pregowski, J. Gorski, M. Zembala, G. Opolski, K. Huber, H. Arnesen, S. D. Kristensen and R. De Caterina The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention J Am Coll Cardiol (2008) 51; 701-7 K. E. Kip, K. Hollabaugh, O. C. Marroquin and D. O. Williams Comparison of coronary flow reserve and fractional flow reserve in patients with versus without diabetes mellitus and having elective percutaneous coronary intervention and abciximab therapy (from the PREDICT Trial) Am J Cardiol (2008) 101; 796-800 A. S. Kini, M. C. Kim, P. R. Moreno, P. Krishnan, O. C. Ivan and S. K. Sharma Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention Am Heart J (2008) 156; 513-9 A. S. Kini, V. H. Chen, P. Krishnan, P. Lee, M. C. Kim, A. Mares, J. Suleman, P. R. Moreno and S. K. Sharma Clopidogrel use and bleeding after coronary artery bypass graft surgery Am Heart J (2008) 156; 886-92 . H. Kim, L. K. Newby, R. M. Clare, L. K. Shaw, A. J. Lodge, P. K. Smith, E. M. Jolicoeur, S. V. Rao, R. C. Becker, D. B. Mark and C. B. Granger Adverse events associated with stopping clopidogrel after acute coronary syndrome JAMA (2008) 299; 2388-9; author reply 89-90 D. H. Kim Bivalirudin versus unfractionated heparin during percutaneous coronary intervention N Engl J Med (2008) 359; 688-96 A. Kastrati, F. J. Neumann, J. Mehilli, R. A. Byrne, R. Iijima, H. J. Buttner, A. A. Khattab, S. Schulz, J. C. Blankenship, J. Pache, J. Minners, M. Seyfarth, I. Graf, K. A. Skelding, J. Dirschinger, G. Richardt, P. B. Berger and A. Schomig Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment Eur Heart J (2008) 29; 1001-10 P. P. Karjalainen, S. Vikman, M. Niemela, P. Porela, A. Ylitalo, M. A. Vaittinen, M. Puurunen, T. J. Airaksinen, K. Nyman, T. Vahlberg and K. E. Airaksinen Thrombogenicity in patients with percutaneous coronary artery intervention and dual antiplatelet treatment Eur Heart J (2008) 29; 1699-700 P. W. Kamphuisen Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk Am Heart J (2009) 157; 502-8 C. D. Joyner, R. J. Peters, R. Afzal, S. Chrolavicius, S. R. Mehta, K. A. Fox, C. B. Granger, M. G. Franzosi, M. Flather, A. Budaj, J. P. Bassand and S. Yusuf Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study Eur Heart J (2008) S. S. Jolly, J. Pogue, K. Haladyn, R. J. Peters, K. A. Fox, A. Avezum, B. J. Gersh, H. J. Rupprecht, S. Yusuf and S. R. Mehta Outcomes associated with combined antiplatelet and anticoagulant therapy Chest (2008) 133; 948-54 S. G. Johnson, K. Rogers, T. Delate and D. M. Witt Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study J Am Coll Cardiol (2009) 53; 1101-9 Y. H. Jeong, S. W. Lee, B. R. Choi, I. S. Kim, M. K. Seo, C. H. Kwak, J. Y. Hwang and S. W. Park Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial Am Heart J (2009) 157; 599-605 S. James, A. Akerblom, C. P. Cannon, H. Emanuelsson, S. Husted, H. Katus, A. Skene, P. G. Steg, R. F. Storey, R. Harrington, R. Becker and L. Wallentin Chronically anticoagulated patients who need surgery: Can low-molecular-weight heparins really be used to "bridge" patients instead of intravenous unfractionated heparin? Catheter Cardiovasc Interv (2009) M. R. Jaff Cardiovascular outcomes after a change in prescription policy for clopidogrel N Engl J Med (2008) 359; 1802-10 C. A. Jackevicius, J. V. Tu, V. Demers, M. Melo, J. Cox, S. Rinfret, D. Kalavrouziotis, H. Johansen, H. Behlouli, A. Newman and L. Pilote Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention Eur Heart J (2009) 30; 290-6 R. Iijima, G. Ndrepepa, J. Mehilli, R. A. Byrne, S. Schulz, F. J. Neumann, G. Richardt, P. B. Berger, A. Schomig and A. Kastrati Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome JAMA (2008) 299; 532-9 P. M. Ho, E. D. Peterson, L. Wang, D. J. Magid, S. D. Fihn, G. C. Larsen, R. A. Jesse and J. S. Rumsfeld Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA (2009) 301; 937-44 P. M. Ho, T. M. Maddox, L. Wang, S. D. Fihn, R. L. Jesse, E. D. Peterson and J. S. Rumsfeld Should we monitor platelet function during antiplatelet therapy? Heart (2008) 94; 685-7 P. Hjemdahl Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study Am Heart J (2009) 157; 733-9 Y. Han, Y. Li, S. Wang, Q. Jing, Z. Wang, D. Wang, Q. Shu and X. Tang The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention J Am Coll Cardiol (2008) 51; 529-35 H. S. Gurm, D. E. Smith, J. S. Collins, D. Share, A. Riba, A. J. Carter, T. LaLonde, E. Kline-Rogers, M. O'Donnell, H. Changezi, M. Zughaib, R. Safian and M. Moscucci Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study J Am Coll Cardiol (2009) 53; 648-57 P. A. Gurbel, K. P. Bliden, J. F. Saucedo, T. A. Suarez, J. DiChiara, M. J. Antonino, E. Mahla, A. Singla, W. R. Herzog, A. K. Bassi, T. A. Hennebry, T. B. Gesheff and U. S. Tantry Adverse events associated with stopping clopidogrel after acute coronary syndrome JAMA (2008) 299; 2389; author reply 89-90 S. K. Goyal and S. R. Punnam Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents J Am Coll Cardiol (2008) 52; 734-9 A. M. Gori, R. Marcucci, A. Migliorini, R. Valenti, G. Moschi, R. Paniccia, P. Buonamici, G. F. Gensini, R. Vergara, R. Abbate and D. Antoniucci Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes N Engl J Med (2009) R. P. Giugliano, J. A. White, C. Bode, P. W. Armstrong, G. Montalescot, B. S. Lewis, T. H. A. van, L. G. Berdan, K. L. Lee, J. T. Strony, S. Hildemann, E. Veltri, F. Van de Werf, E. Braunwald, R. A. Harrington, R. M. Califf and L. K. Newby Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol (2008) 51; 256-60 M. Gilard, B. Arnaud, J. C. Cornily, G. Le Gal, K. Lacut, G. Le Calvez, J. Mansourati, D. Mottier, J. F. Abgrall and J. Boschat Ensuring appropriate use of antiplatelet agents in the treatment of acute coronary syndromes--have cardiovascular physicians been given enough grace in getting it right? Heart (2008) 94; 135-7 A. H. Gershlick Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease Heart (2008) 94; 743-7 T. Geisler, M. Kapp, K. Gohring-Frischholz, K. Daub, C. Dosch, B. Bigalke, H. Langer, C. Herdeg and M. Gawaz Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial J Am Coll Cardiol (2009) 53; 837-45 A. Y. Fung, J. Saw, A. Starovoytov, C. Densem, P. Jokhi, S. J. Walsh, R. S. Fox, K. H. Humphries, E. Aymong, D. R. Ricci, J. G. Webb, J. N. Hamburger, R. G. Carere and C. E. Buller Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial J Am Coll Cardiol (2008) 51; 1645-52 F. Feit, S. V. Manoukian, R. Ebrahimi, C. V. Pollack, E. M. Ohman, M. J. Attubato, R. Mehran and G. W. Stone Guidelines for anticoagulant use in acute coronary syndromes Lancet (2008) 371; 1559-61 J. Eikelboom, G. Guyatt and J. Hirsh Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin Am J Cardiol (2008) 102; 396-400 M. A. Duzenli, K. Ozdemir, N. Aygul, A. Soylu and M. Tokac Interaction between cigarette smoking and clinical benefit of clopidogrel J Am Coll Cardiol (2009) 53; 1273-8 N. R. Desai, J. L. Mega, S. Jiang, C. P. Cannon and M. S. Sabatine Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individuEarly glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis al patient data meta-analysis Hof Heart (2008) 94; 1548-58 G. De Luca, C. M. Gibson, F. Bellandi, S. Murphy, M. Maioli, M. Noc, U. Zeymer, D. Dudek, H. R. Arntz, S. Zorman, H. M. Gabriel, A. Emre, D. Cutlip, G. Biondi-Zoccai, T. Rakowski, M. Gyongyosi, P. Marino, K. Huber and A. W. van't Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes Heart (2008) 94; 159-65 O. H. Dabbous, F. A. Anderson, Jr., J. M. Gore, K. A. Eagle, K. A. Fox, R. H. Mehta, R. J. Goldberg, G. Agnelli and P. G. Steg Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris Am J Cardiol (2008) 101; 1700-3 T. Cuisset, M. Hamilos, J. Sarma, G. Sarno, E. Wyffels, M. Vanderheyden, E. Barbato, J. Bartunek, B. De Bruyne and W. Wijns Adjusting clopidogrel loading doses according to vasodilator-stimulated phosphoprotein index: on time, too early, or too late? J Am Coll Cardiol (2008) 52; 790-1; author reply 91-2 T. Cuisset, C. Frere, J. Quilici, M. C. Alessi and J. L. Bonnet Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study Circulation (2008) 118; 1225-33 J. P. Collet, J. Silvain, A. Landivier, M. L. Tanguy, G. Cayla, A. Bellemain, N. Vignolles, S. Gallier, F. Beygui, A. Pena and G. Montalescot Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet (2009) 373; 309-17 J. P. Collet, J. S. Hulot, A. Pena, E. Villard, J. B. Esteve, J. Silvain, L. Payot, D. Brugier, G. Cayla, F. Beygui, G. Bensimon, C. Funck-Brentano and G. Montalescot Emerging transcatheter therapies for aortic and mitral disease Heart (2009) 95; 148-55 R. D. Christofferson, S. R. Kapadia, V. Rajagopal and E. M. Tuzcu Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy Am Heart J (2008) 155; 239-44 . P. Chew, Z. Huang, K. S. Pieper, H. White, K. W. Mahaffey, J. J. Ferguson, R. M. Califf and P. G. Aylward Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction Circulation (2009) 119; 1195-202 S. Cheng, D. A. Morrow, S. Sloan, E. M. Antman and M. S. Sabatine What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice? Catheter Cardiovasc Interv (2008) 71; 816-21 B. R. Brodie Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions J Am Coll Cardiol (2008) 51; 2220-7 S. S. Brar, J. Kim, S. K. Brar, R. Zadegan, M. Ree, I. L. Liu, P. Mansukhani, V. Aharonian, R. Hyett and A. Y. Shen Impact of a 600-mg loading dose of clopidogrel on 30-day outcome in unselected patients undergoing percutaneous coronary intervention Am J Cardiol (2008) 102; 1318-22 L. Bonello, G. Lemesle, A. De Labriolle, P. Roy, D. H. Steinberg, T. L. Pinto Slottow, Z. Xue, R. Torguson, W. O. Suddath, L. F. Satler, K. M. Kent, A. D. Pichard, J. Lindsay and R. Waksman Emergence of the Concept of Platelet Reactivity Monitoring of Response to Thienopyridines Heart (2009) L. Bonello, A. De Labriolle, M. Scheinowitz, G. Lemesle, P. Roy, D. H. Steinberg, T. L. Pinto Slottow, R. Pakala, A. D. Pichard, P. Barragan, L. Camoin-Jau, F. Dignat-George, F. Paganelli and R. Waksman Bivalirudin with provisional glycoprotein IIb/IIIa inhibitors in patients undergoing primary angioplasty in the setting of cardiogenic shock Am J Cardiol (2008) 102; 287-91 L. Bonello, A. De Labriolle, P. Roy, D. H. Steinberg, T. L. Pinto Slottow, Z. Xue, K. Smith, R. Torguson, W. O. Suddath, L. F. Satler, K. M. Kent, A. D. Pichard and R. Waksman Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy Catheter Cardiovasc Interv (2008) L. Bonello, A. De Labriolle, G. Lemesle, D. H. Steinberg, P. Roy, R. Torguson, W. O. Suddath, L. F. Satler, K. M. Kent, A. D. Pichard and R. Waksman Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol (2008) 51; 1404-11 L. Bonello, L. Camoin-Jau, S. Arques, C. Boyer, D. Panagides, O. Wittenberg, M. C. Simeoni, P. Barragan, F. Dignat-George and F. Paganelli Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis Am J Cardiol (2009) 103; 5-10 L. Bonello, L. Camoin-Jau, S. Armero, O. Com, S. Arques, C. Burignat-Bonello, M. P. Giacomoni, R. Bonello, F. Collet, P. Rossi, P. Barragan, F. Dignat-George and F. Paganelli The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol (2008) 52; 531-3 K. P. Bliden, J. Dichiara, L. Lawal, A. Singla, M. J. Antonino, B. A. Baker, W. L. Bailey, U. S. Tantry and P. A. Gurbel Cytochrome P450 2C19 polymorphism and clopidogrel after MI Lancet (2009) 373; 1171; author reply 72-3 S. Bhattacharyya and R. Rakhit The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial Am Heart J (2008) 155; 687-93 P. J. Best, S. R. Steinhubl, P. B. Berger, A. Dasgupta, D. M. Brennan, L. A. Szczech, R. M. Califf and E. J. Topol Incidence, predictors, and clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy Am Heart J (2009) 157; 164-9 O. F. Bertrand, E. Larose, J. Rodes-Cabau, O. Gleeton, I. Taillon, L. Roy, P. Poirier, O. Costerousse and R. D. Larochelliere Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis J Am Coll Cardiol (2008) 52; 1693-701 J. S. Berger, C. B. Frye, Q. Harshaw, F. H. Edwards, S. R. Steinhubl and R. C. Becker Comparison of the impact of short (<1 year) and long-term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality Am J Cardiol (2008) 102; 1159-62 S. Banerjee, C. Varghese, J. Samuel, R. A. Weideman, B. B. Little, K. C. Kelly, S. V. Rao, R. F. Reilly and E. S. Brilakis Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial Am Heart J (2009) 157; 369-74 H. D. Aronow, S. R. Steinhubl, D. M. Brennan, P. B. Berger and E. J. Topol Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial) Am J Cardiol (2008) 102; 1285-90 H. D. Aronow, R. M. Califf, R. A. Harrington, M. Vallee, C. Graffagnino, A. Shuaib, D. J. Fitzgerald, J. D. Easton, F. Van de Werf, H. C. Diener, J. Ferguson, P. J. Koudstaal, P. Amarenco, P. Theroux, S. Davis and E. J. Topol Optimizing clopidogrel therapy before stent implantation: should clinical setting be taken into account? J Am Coll Cardiol (2008) 52; 1349; author reply 49-50 D. Aradi, A. Vorobcsuk and A. Komocsi Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis J Am Coll Cardiol (2008) 51; 2028-33 E. M. Antman, S. D. Wiviott, S. A. Murphy, J. Voitk, Y. Hasin, P. Widimsky, H. Chandna, W. Macias, C. H. McCabe and E. Braunwald Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment Am J Cardiol (2008) 101; 440-5 D. J. Angiolillo, M. A. Costa, S. B. Shoemaker, B. Desai, E. Bernardo, Y. Suzuki, R. K. Charlton, M. M. Zenni, L. A. Guzman and T. A. Bass Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel J Am Coll Cardiol (2008) 52; 1052-9 L. Ang, V. Palakodeti, A. Khalid, S. Tsimikas, Z. Idrees, P. Tran, P. Clopton, N. Zafar, G. Bromberg-Marin, S. Keramati and E. Mahmud Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative) Am J Cardiol (2008) 102; 1335-40 D. Alexander, N. Mann, F. S. Ou, E. D. Peterson, E. M. Ohman, W. B. Gibler and M. T. Roe Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention Am J Cardiol (2008) 101; 1413-7 A. Aggarwal, D. Dai, J. S. Rumsfeld, L. W. Klein and M. T. Roe Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents Am J Cardiol (2008) 102; 401-3 M. Abuzahra, M. Pillai, A. Caldera, W. B. Hartley, R. Gonzalez, J. Bobek, H. Dokainish and N. Lakkis